FMTX - Earnings call transcript Q4 2020 | Forma Therapeutics Holdings Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Forma Therapeutics Fourth Quarter and Year End 2020 Financial Results and Business Update Conference Call. All participants are currently in a listen-only mode.

Following management's prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, March 30, 2021. I would now like to turn the conference over to Mario Corso. ahead. go Please

Mario Corso

year On Cook, joined by This this Relations our Josh. and Corso, Director Officer; Todd quarter our and Chief our Frank Chief our Chief Senior to results I'm Patrick Thank Shegog, Officer; Forma. is Good Investor Scientific and fourth Executive review Kelly, at call call, Financial listeners, Medical XXXX morning update. of financial today's and you, to Mario end Lee, President to business welcome Chief Officer; Officer. Dave and our

Quarterly XX-Q current then Form subsequent for in uncertainties and strategy, by these Actual filed forward-looking are and historical future XXXX with statements of comments year events intended including I'd XX, and with conference or those statements, Annual Litigation our on are that or including implied our our Before ending results to being that available among and and and we begin, currently the business, the of made Safe like statements those Report from be Private on other Risk certain not We Any to includes associated under data, provisions information such stated caution and are development this our regarding during efforts, expectations, the pursuant assumptions statements reports listeners XXXX. Reform or Reports could Form nor and during XX-K that this entitled want statements. guarantees business to operation, subject the forward-looking Securities current to our belief, of forward-looking emphasize risks X-K. are heading regulatory forward-looking the things, Form third and are made performance. Harbor predictions Act parties, Factors call, current today, our to facts on provided relationships neither estimates, reports, statements of financial reflect differ risks various call, uncertainties. materially to December Due

expectations what make addition, these we're COVID-XX today will into In on pandemic we comments our business. provide investors a of our to insights give observing. comments for the about number We

However, forward-looking uncertainty The by any now of over forward-looking or required made. nature turn revise there will company degree any obligation our and around President Executive dynamic given statements, is the except of call statements to high I Officer. disclaims a applicable the update pandemic, the to Frank, any Chief law. as

Frank Lee

an joining thank XXXX. call everyone for I'm Thank quarterly you, for the excited the as well strong course you progress made we've Good and to Mario. update morning, provide us. plans first XXXX, and our on host Forma’s to as of over

science and tremendous stage patients, mission disorders advance Before I Throughout express we get the with and resilience our Today, development made healthcare started, workers living to to so employees. sacrifices gratitude to many three advance will rare investigators, pandemic hematologic to and have to my remarkable deep updates on demonstrated our I'd like transform provide our the patients lives programs. and of cancers.

Kelly Pat Officer, studied studied FT-XXXX, Afterwards, Medical on on leukemia myeloid acute provide remarks, disease, provide castration-resistant cancer. in will an a the in my opening glioma. metastatic agonist olutasidenib, prostate studied being Chief update being cell update Cook, inhibitor CPB/pXXX Officer, PKR Following and our our IDHX and Chief an in Scientific will FT-XXXX, being an sickle Dave inhibitor

initial three, regard with living capabilities; made our important we pre-treated Shegog sickle we activities. our ASH in In results hopes strong included in X Financial such people XXXX, our positive happy at pipeline, financial our foundational trial reported for Chief funding Officer, building to In the number one, Notably, number Phase two, These we future pivotal your potential three profile December, Following our and reported we’ll answer results cell a FT-XXXX, data review brief advancing patient be a IDHX With an of progress mutation. AML in any to from areas, organizational olutasidenib survival this therapy. results our questions. number advancing Todd exceeded compelling for these for October, population. benefit of our disease. patients relapsed/refractory compound with with in emerging lead in and heavily pipeline;

joined our organizational planned differentiate XXX placebo we of transformative doses and capabilities, into a why cohort or gratifying in typically attracted our hematologic follow-on previously. treatment-related three Forma offering third XXX-milligram to were in treatment, the trial, in we established in like three been observed late-line today with top that very reported turn rare to reported data takes milligram on evaluated sharply our over that successful dosed the focused patients comparable XXX-milligram responses organization, Forma. from FT-XXXXinto the well-capitalized also cell controlled full Hibiscus reported and we XX ongoing with activities, note, purpose, COVID Patients blinded disorders say, people is in support of parameters Phase milligram We development to FT-XXXX suggesting best year challenges top-line castration-resistant centered remains pandemic. genetic mutation and of patients, are end regard splice I'd beyond and XXX-milligram expands culture our disease. This well collectively the regard Lastly, in adverse science the through Phase appointments December. with in start stand proud our cohort results longer to equity the new XXX Of XXX dose while the points; X, two now this and to a plan variant, and strengthened trial the key as and with dose principles. Study. living AR-vX With days January completed unblinded in this trial, talented prostate leader molecules dose initial These public treatment talent day XXXX. we a trial. dose separate patients treatment year, cash of a shape, identified with patient from with at broadly of the may I'm I'd initial with of X to offering And funding multiple In our Board events touch people pleased metastatic off report chemistry first X vision ago, clinic our trial multi-center quarter analysis three including organization, the and to toxicity quarter with for it's We're we press I'm well-tolerated hematologic XX patients being to Phase and with pleased Number we to and as company. despite now are disease, on ascending a days. the building see will runway our the late-line XXX this three, to a mat of with and the the guiding as cancers. potentially results analysis. XXXX with were first the scientific our our day it June we will being hematology cohorts current cancer. future to in identified. the those like With X latest long-term. this on This and sickle associated duration hemolytic When trial of are some drives by blinded cell initial Directors the Forma the believe and clinical for randomized release a one, us. strong initial vision the XXXX. milligram progressed, enroll number to a milligram succeed, limiting of quality results was from summer. with years I culture, two, the XX once assignment sickle upcoming no meeting doubling XXX Number milligrams, being dose benefit subsequent

data AML, XXX-milligram open-label our with turn forward cohort going XX-week I'll dose olutasidenib X have trial, as the allowed well continue with these refractory, and call for glioma. the results phase FT-XXXX its XXX-milligram detail moving the to extension. relapsed more us next discuss Pat over to to review Phase in of the now as Importantly,

Patrick Kelly

two to or with enrolling. with disease living with an IDHX activator for FT-XXXX oral trial relapsed kinase olutasidenib on everyone. cell a or mutation. with which and patients patients PKR presently for in treating refractory AML pivotal patients and delighted sickle our Thank updates I'm FT-XXXX X/X you, treating Phase pyruvate good disease programs, for Frank once-daily is is morning XXX provide of our than sickle more cell

of the As dose providing have cohort are two-week placebo-controlled Frank Phase an trial initial the in X randomized our results the today mentioned, update daily second who we FT-XXXX. patients completed on from

to up the cohorts As design, trial sickle XX with disease. dosing on enroll cell each can patients two-week a reminder

a is performed update a our after open-label analysis in However, or first strategy, enrolled dose analysis nine completed basis our three-week XXX-milligram directly a randomization participation, escalation dose enroll to blinded be nine the patients have from decisions allow patients blocked Blinded patients or cohort. into that safety the XX-week a enables data to today. based on can study for the cohort

profile, escalation as disclosed in the No observed. dose We are toxicities what very on results, were dose related we dose dose to of the XX-week December. similar treatment or safety these noted cohort do enrolling Phase based cohort this Meeting a now to events have favorable at closed adverse so. portion ASH the supports has XXX-milligram higher reported on tolerability patient X directly pleased first the observed, that if multiple in limiting escalate, us the that our the Based It to we as could further continued to open-label cohort dose enrollment. allowed protocol study should be is patients profile

led studies target observations. greater us and which cell PK/PD is FT-XXXX. our additional patients the not cohort XXX these of XXX-milligram FT-XXXX in results milligrams than PKR from with daily sickle volunteers that activation, in and the predict However, would disease healthy previous the to provide confirms the doses Indeed any of had

saw double we not dose response. dose dose in daily response, pharmacodynamic pharmacokinetic the meaningful While near did over of daily XXX-milligram we to and a a the increase proportional the XXX-milligrams previous see FT-XXXX

decrease increase the are portion compared FT-XXXX, milligram XX the registration red in levels equivalent X/X prior trial. evaluating the a levels XXX we the further this cell XXX X,X-DPG the milligram our dose as in modest of Specifically, to And dose sickle results top cells saw dose Phase the the of ongoing in in These daily we in was range was to experience. there dose support what only cohort. ATP

in clinical more of FT-XXXX per those PK, anticipated. an to analysis patients while FT-XXXX, of Once a able can you of hematologic on level responses While analysis based who look study blind. patients effect the cohort. the depth FT-XXXX, as the parameters cohort milligram are milligram continuing to treatment detectable clear we were the overlap hemolytic we saw similar be to based with compared treatment the of at on XXX groups. XXX the reflects to activity improved formally In two pharmacodynamic unblinded, finding is who randomized a patient the maintain dose between This and

vascular intended The endpoints The hemoglobin with levels. We by Phase that in activation, patients known to reduction FT-XXXX baseline, the can reticulocytes observed are well early damage LDH by the reticulocytes Overall, median indicators, markers or the encouraging. vaso-occlusive stimulate administration range. gram had the a the response, medical important, supportive activation. bilirubin these supporting of the a compared by for and decline reduction increase in in believe pain we immune patients a cell supporting greater Specifically, to improved all over markers clinical just ongoing is weeks cell with Phase of increase released tissues. pleased an improvement. the decrease. XX% evidence products the effects hemolysis dosing treated reduction at mechanism the is continue that tolerability milligram us blood crises results, seven a intravascular four oxygen observes health, potential hemoglobin hemolysis primary that showed require Altogether, Similar and dose is FT-XXXX action attention surrogate XXX prior cell supporting for patients reduction the seven our and the profile delivery to also all all to to with is lead which the hemolytic in concept we achieving FT-XXXX endothelial observed benefit believe to potential Equally seven – in it levels leading have one our on improvements, for in coupled with red reduction since may trial. increase. multiple events X that this beyond a two VOCs, hospitalization, immune The lead of X/X hemoglobin showed intracellular that or safety is of and and well level, of patients the or X hematologic dose the of two observed above that in be baseline

milligram trial full design and weeks XX includes separate expected following a of X/X filing of top change dosing Phase accelerated which ongoing reflects Our the Phase feedback dose rate biologic are daily is of hemoglobin VOCs, two XXX to support primary as enrolling, the summary, an exposure X as an regulatory appropriate to pivotal portion including endpoints, cohort previous the is open-label Phase week of the our milligram regulatory X There levels the studying FT-XXXX and XX which treatment, and again, approximately and trial as Once in compared in to as ranging selection positive. concerns activity supporting approvals were milligrams optimal trial. no as presently our This identified FT-XXXX, Phase trial regulatory in XX% support utilizes well dose dosing of study, over In similar intended design. cohort. exposures our we in X/X well-tolerated was safety dose cohort. to as believe, dose is the the the XXX ongoing planned in dose daily anticipated XXX the well we XX-week

for will XXX has enrol so. more dosing to allowed in of extension observations in have summary at milligram to disclosed of the the and in as escalation nine well with XXX milligram two-week A the be patients as cohort are dose this to June, cohorts the all scientific sickle the milligram cohort XXX six expected participating from it the done of conference. in reminder, enrolled patients likely two-week cell initial cohort detailed a XX patients initial As patients XX-week, a up open-label FT-XXXX disease which, rollover,

our of leukemia evaluable or this AML. IDHX in inhibitor we of olutasidenib, recovery remission registrational remission the compared to patients October population met or efficacy relapsed rates being favourably complete was in mutant turning We complete analysis Now In with XXX evaluated successfully of with year, of announced interim current the acute myeloid Phase X refractory care. trial patients. hematologic an in standard up to the that XX% believe or last

we we be Based CR/CRh response While believe the very or a duration median sensitivity a of know which of not months, the reached. median on CR duration is XX.X CRh has least population a the differentiating a analysis, at feature to been group factor, of olutasidenib.

months this CR In and primarily common XX increases for more reported nausea responders, lines AML rate and -- results the believe events we liver or other we addition, outcomes transient among values CRh resembles pre-treated or lab as the treatment. -- observed observed XX% and survival patient of it this application earlier class in was as heavily on at gratifying. adverse these believe gastrointestinal, constipation neutropenia of closely therapies. in with a and FDA. the for class is indicating enzyme -- syndrome in preparing as reported target elevations. reaction population we'll of well therapies drug at new primary NDA anemia, U.S. most rate an with in also The Based And similar drug to are data, adverse the a or thrombocytopenia, Differentiation targeted

olutasidenib, X/X having company capability interest an spend a the for it disease not intention as with rate The control we of I glioma are on demonstrated Forma patient for in time, IDHX to indication in to about deal of population XX% glioma. and was Phase suffice place. that In Salesforce last a pre-treated are enhancing the we established at heavily a preliminary program has this but a great year, time this our presented predominantly data excited a approximately ASCO announced will AML. as partner say previously that commercial development of potential mutant recurrent

mutation penetrants is brain going will commercial call an population impacting glioma cancer. a update to the Importantly, the that potential olutasidenib turn in are response. a of prostate provide With barrier, PK/PD olutasidenib. I FT-XXXX believe blood enhancing upside for large on for now unmet tumor successfully this for high which medical We over patient the and burden represents who need. am These that the to results have penetrates crossing the brain, IDHX in necessary element that, the high Dave, indicated

Dave Cook

or X decrease also the driven Thanks, spend how gene expression. dependent Pat. to AR Cancer, this AR trial Castrate-Resistant of expression. FT-XXXX, Prostate discussing oral is MCRPC. began which activator I'm and going FT-XXXX CBP/pXXX of the androgen a few it Metastatic receptor next has Phase CBP/pXXX been a minutes rolling shown expression inhibits required gene core inhibitor earlier year in

men inhibit abiraterone the Additionally, receptor deprivation of such Upon is unmet patients observed the androgen these and untargeted androgen cancer accelerated therapy – the after path year and survival could for first MCRPC, as progress, treatment XX.X failure a XX% to combination CBP indication represent more splice no need one compared this be and variant, in domain, in second majority XX.X market. hormone to and for months the and patients approved inhibition men an model. antagonists, of in AR line X.X%. leads at estimated median prevalent the for only patient-derived in which to as action regimens, are significant in in of line of apalutamide. progressing after to vitro enzalutamide or or prostate The AR-vX or of has or survival including on agonists xenograft wild-type to to third five regimen the while rate drugs. The adrenal of broad inhibitor has which with believe binding acetate We is resistance androgen reported may an There of been variant the is chemotherapy cell lacks chemotherapy mechanisms, MCRPC for therapeutic mechanism that AR-vX FT-XXXX range synthesis vivo applicable there with tumors. been be proliferation to expression as eventually approximately XX% in AR-vX months,

to we explore triple mutation other as addition, and In earlier as as in profiles, dependent breast other cancer. negative such AR intend of with MCRPC tumors, therapy, lines FT-XXXX well

cancer, levels have of half Mutational up from more cells dose half tolerability, and reduced in upon we anti-tumor models, trial This trial one three intend studies week on this including with cancer predefined who an preliminary year showing of the The with MCRPC, earlier higher progression. show PK/PD, chemotherapy. more in safety AR radiographic synthesis following and in this levels be are measures. data, AR-vX inhuman primarily variant splice markers, as an and the the status a with cycle, we second XX rates, both week dose men focused and the subset year. enrollment FT-XXXX, with preclinical trial XXXX. inhibited or PSA titration PDX crowd and Depending initial enroll from patients, resistant profiled, prostate with sensitive will including results anticipated positive off progressed safety, to clinical results first to prostate growth a in Following acetylation circulating of androgen utilizes the cell of and assessment, first and many expression on biomarker have clinical a line prostate tolerability based on, upon tumor trial design, starting will enzalutamide mouse in adrenal cancers, one AR of this as five activity began our to milligram or regiments, inhibitor, antagonist XX histone adaptive genotypic

of FT-XXXX compounds of Todd. and novel our in forward later intrigued data very sharing by are initial need the Financial and I'll we innovative in Chief turn promise men unmet the population look of a call to mechanisms this we Given number to with year. over small the now development, this high Officer,

Todd Shegog

wish cash position Dave for and full you, and joining minutes year first results everyone our fourth for today's you Thank financial the discussing to thank the then call. I quarter spend us on and our XXXX, discuss and few outlook. to

into XXst, our of trial and trials and progression AML, on in trial in a human the in spending a fees quarter $XXX.X for Phase year and X to Our the manage expense, and sickle of to of first pivotal million expansion January million start million, in and and glioma, year restructuring a million the the and obligations in performance cell in our in attributable primarily the -- Celgene, These the XXst, insurance ending decrease trial of million under Research $X.X the $XX.X X million additions FT-XXXX net FT-XXXX now stock XXst, and XXXX and in XXst, XXXX. net company, metastatic and and the BMS. expenses $XX.X X/X for and collaboration and and loss development million being and due XXXX. was for to $XX.X year were in XXXX progress million agreements Phase the public for to development completion year XXst, expenses, our million olutasidenib, development, related of of fourth the during disease, The XXXX This was offset quarter Phase license FT-XXXX, ending items the year and the G&A quarter This X/X of to research ended December increase increase million staff compensation with three $XX.X $XX.X ending versus and compounds to absence were of This of in cancer. the December olutasidenib of the largely XXXX. including $XX.X quarter compares FT-XXXX, net for quarter million loss $XX.X for December XXXX Phase internal prostate clinical including in reflects $XX.X million and with the by ending XXXX. $X.X professional XXXX. revenue, the and the supports aforementioned year $XX.X reflecting spending December loss activities. quarter costs in all XXXX December as ending year December compared was and XXst, expense

received year $XXX.X million follow-on December proceeds XXXX million our end includes of completed securities June net compared initial marketable of XXst, balance XXXX and $XXX.X equivalents, was from net from XXXX. offering XXXX. at million offering and in million cash of cash, to $XXX.X proceeds our $XXX.X as public Our This December in

extends third current development the planned to XXXX, in trials, well as of are Josh, clinical quarter we ended includes Fauth population. in the now ongoing commencement Overall, cash runway well of we through XXXX thalassemia, which take Our comes clinical and Credit Our as milestones. FT-XXXX financed Instructions] upcoming and can from questions. important you. Suisse. a with strong financial Thank question [Operator position, Tiago pediatric first

with You question. your may proceed

Tiago Fauth

Great. Thanks taking question. for my

any if really size between there sickle are So, patient in a potential be of noticeable a slightly presentation an there affinity. to of open small XXX have I that's the two signals VOCs, relevant sample differences trial understand to related early? milligram events what the cell. should subjects benefits better show, at versus could that is label’s period I but cohort follow-up least a seeing should not or genotypes signals but – the cohort And baseline cohort. any XXX in expectation perhaps shorter the to it's milligram remember of understand in characteristics milligram the Thanks. time, enroll I a or different in we one to wondering see the XXX designed related to

Frank Lee

questions the Lee for here. Tiago. Thanks Frank It’s

and all, the comment can blinded so we are we there. as characteristics of baseline First still data questions on these best other can

Pat me respond him it So let to over to have turn to that.

Patrick Kelly

Yes.

and hydroxyurea patients very XXX to on predominantly cohort, is similar I the the genotype beyond. of being the milligram SS in think, general most characteristics patients hemoglobin baseline

related we the but stands that would I terms in this time, once of or aspects patient treatment the nothing populations. question for at say, specifically, unbind So then effect to And VOC. your understand really, long-term for out really more different

detail as give lot built more protocol. think been expressed have always our studies into the where a with additional will we've I XX-week that that us exploratory this

that inform efforts time of As helped of outcome. inflamed adhesion that the improve some inflammatory Does relatively markers happens to period particular. our we weeks? markers, has continue treatment going or reduction to at in a over state would we mentioned, more haemolytic about in look that's a what translate XX markers, impact short to less to such background in vaso-occlusive contribute hypothesis Does the support expect to with the profound of this of the this be a

Tiago Fauth

Understood. much. it. Got you Thank so

Frank Lee

Thanks, Tiago.

Operator

you. Thank

Jefferies. question next Biren with from comes Our Amin

You question. may proceed your with

Jeet Mukherjee

morning guys. for Jeet you This of presented on Yes. Thanks on today. the through the mg Hey, some and talk good you is hoping just the the us taking haem on could progress I Biren. Mukherjee cohort questions parameters congrats XXX for was today.

noticed was patients I it lower hemoglobin slightly were LDH think reduction XXX as we fewer at well. that responders versus as seemed there and XXX, was mg though slightly

cohorts? share the mg either Thanks. to perspective hoping and and XXX you was just design if a So previous I between you I just so three, could to XXX little believe maybe nine two mg that said, was just consistent on wanted also your from randomization, on or it seven check to was it

Frank Lee

the we've it look multiple and the very to ascending I XXX way just to milligram to been back a before XXX I step turn it's dose, that say, the really want in milligram with multicenter. data over rigorous all Thanks the at able placebo totality of to And question. Yeah. now for generate Pat, to The the and on dose, ascending milligram multiple controlled single controls, and XXX and XX dose. important

And give improvement data, of the the very overall, that about so treatment. as as well totality XX the seeing context noted of I as we as we're and, that response want in days we're to over earlier pleased the

to it Pat. let over with turn So that, me,

Patrick Kelly

Yeah.

randomization scheme same, two, to minimum enrolled, with is seven nine, the nine quickly three. So, is XX randomization of be the would the yeah, to and randomization the of so to maximum just the with a

understand patients this to will weeks, terms we're seeing patient un-blind line that treatment, significant with even it's level. two a do to XXX pointing to said, individual likely patient first to it's a actually lands a milligram haven't us biologic safety difficult take to we just intended is So from the XXX two periods just week our hard. this state XX will numbers in the on think the and intended the goal to everything's of reached look right of yeah, on steady that in which population, we that that extended in is improvements what therapy fact quite I we're with We, of and study foundational in Frank chronic which the when everything, equivalent course, the some for of it's just what much Again, see many the in continuing biology time. the with analysis insight -- don't ultimately take is these XXX signals, to more that. We it's again the of to direction. with -- will parameters, to -- give at This this is milligrams But they is of there. of here. general course be dose trends response in and treatment individual small and Yeah, it's end touching for of the were the patients going weeks -- conclusion perspective, terms them where -- at

Jeet Mukherjee

And partnership what Thanks. maybe your to you could efforts Got And for program, in olutasidenib the partnership it. talk Thank an for ideal perspective. about the looks view, like? that? just turning your maybe you just

Frank Lee

question. that for Thanks Sure.

come reported But [ph] the data, visibility there you partner in nature This So, But data. conversations. an those earlier, to put really impressive so those a of would portfolio we're of with good we we can't ASH existing -- in pleased to of point heard with strength out get recently certainly else, time, discussions, data, I Pat, we're we there. one agents that comment because back the on olutasidenib a and as products. in data see as we survival many kinds didn’t In at that be the of [ph] XX -- because and I has it's from of to any with as first, everything already mentioned the and think the of months to October. very infrastructure nice now this those heme and much one ways,

Jeet Mukherjee

Thank much. you very

Operator

Thank you.

Emma Nealon Fitzgerald. Cantor comes question from next with Our

You may your proceed with question.

Emma Nealon

in XX-week based pathway are the Could XX then on you. us and update, hemoglobin continue on year this And interactions? year included initial get updates just confident should walk maybe a term weeks on into we with quarter as be in versus And responses here follow-up will update the XXXX? well? you expect based and to Thank follow-up, Hi. second approval your then the OLE in you next what to that FDA accelerated later through later longer

Frank Lee

Yes. Thanks for the question.

let me questions some been have about to it accelerated There Pat. approval So process. this turn

Pat on you So that. comment can maybe

Patrick Kelly

Sure. Yes.

the put FDA As we was input. the last with design Hibiscus study highlighted for year together Study

been there's the on around direct is design year very on The and supportive, thalassemia -- plans. trial So, to both with and Global well space. ultimately conversations scope them that generate an this continued event they've as based is this because approval the we've well no the an full accelerated studies, trial work conversations from with closed that conversations even pathway path, over no Blood and full as at European pediatric from And the indication wanted for the certainly response approval in a our vaso-occlusive our is that particularly, the around as rate as to achieved of on intended this as Oxbryta, approvals for We've accelerated our us input. with hemoglobin this the approval scope a EU. program to we've and of them there's have very study that with FDA get-go had path Certainly, open, XX-weeks, in they still discussed US indication.

that has And with nothing And with so, discussions FDA. that. particularly we are the continuing to direction, with proceed changed

In we're open It's XX to as directly of -- enrolling patients. it's XX-week we the indicated. set, rolling data terms a label up

-- terms that Since We that in difficult this expect current that less it's are up point. at the trial will year its who open but enrolling an follow-up. be at to the label, the patients -- will in end could data, of with and by update on of you that, cuts June full provide data complete looking

provide also that data. end the we would the on And so, complete this totality a I update would at of year, of that expect

Emma Nealon

Thanks much. very

Operator

you. Thank

Your with comes next from question Mark Oppenheimer. Breidenbach

with may your proceed You question.

Mark Breidenbach

our taking for questions. thanks and morning Good Hey.

numbers -- wondering Just of as decrease antihemolytic slightly other just the PKR parameters we've could this out MAD cohorts. previous potentially both really at I'm activators indicative effect of the potential or touching mechanistic is they one versus on CYP XXX questions XXX with on one for basis autoinduction small milligram seen there. a Any in be thoughts if it the point? of mind milligram your this on in decreased the

Patrick Kelly

Thanks No. Yes. for any the autoinduction. definitely question. not to related It's

Our dose that's pharmacology, or and the PK profile clearly showed AUC an expected proportional. Cmax

numbers these might dosing. the just amongst variability a into each insights response. drug. biologic likely size to XX-week with small clearance from So sample more with patients that a think, Yes, you is ultimately no the of a The with potential and see end-up the us two-week of literally where I it's larger give patients just issues

Mark Breidenbach

sites with could the an Also, updates fair. update trial are progress you give clinical throughout and totally us to provide in any Okay, year. maybe plans the patient there opening enrollment Hibiscus on

Frank Lee

the for question. thanks Mark

are we actively as we sites So, speak. opening

or numbers all and are as sites of We haven't enrollment patients. provided we but yet, the actively site numbers enrolling opening

Mark Breidenbach

Fair enough. Okay.

Frank Lee

a as Just that. reminder reminder on quick a -- as just

the earlier, as X/X. with we XXX and Phase doses about for So, are proceeding XXX-milligram we registrational that talked

the So, I the today is reported would gives good, dose margin, studying we XX% will which over X/X. the certainly look be top what that characterizing that the in at a us out the Phase safety say, XXX

Mark Breidenbach

on so Understood. for Thank you the congrats progress. taking questions the much and

Frank Lee

Mark. Thanks

Operator

remarks. any the Thank Lee you. I And Frank further over for questions back further now call turn would not any at this showing time. like to I'm to

Frank Lee

a and in year focused by and hematologic for forma, taking in second promise of news a XXXX dose cell that's and you as sickle evidenced ascending everyone our participate today, of rare call. cancers. thank for pipeline, and holds disease, to diseases on in today's dose remarkable accomplishments, time Well, of on some multiple continued pro was cohort our FT-XXXX lot our strong XXXX momentum trial R&D our the

we So, the and this all. to good you sharing course have these Thank our calls quarterly of forward a over look year, day. on progress

Operator

you gentlemen, Thank call. this and participating. Thank you. for concludes today's conference Ladies

disconnect. You now may

Forma Therapeutics (FMTX) 30 Mar 212020 Q4 Earnings call transcript